RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz S Nowakowski; Dok Hyun Yoon; Patrizia Mondello; Erel Joffe; Anthea Peters; Isabelle Fleury; Richard Greil; Matthew Ku; Reinhard Marks; Kibum Kim; Pier Luigi Zinzani; Judith Trotman; Lorenzo Sabatelli; Eva E Waltl; Mark Winderlich; Andrea Sporchia; Nuwan C Kurukulasuriya; Raul Cordoba; Georg Hess; Gilles Salles

doi:10.1007/s00277-023-05196-4

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil (Co-author), Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E Waltl, Mark Winderlich, Andrea Sporchia, Nuwan C Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

12 Citations (Web of Science)

Original language	English
Pages (from-to)	1773-1787
Journal	ANNALS OF HEMATOLOGY
Volume	102
Issue number	7
DOIs	https://doi.org/10.1007/s00277-023-05196-4
Publication status	Published - 2023

Keywords

RESPONSE CRITERIA
SINGLE-ARM
PHASE-II
MULTICENTER
RITUXIMAB
OUTCOMES

Access to Document

10.1007/s00277-023-05196-4

12 Citations
1 Correction

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
Nowakowski, G., Yoon, D., Mondello, P., Joffe, E., Peters, A., Fleury, I., Greil, R., Ku, M., Marks, R., Kim, K., Zinzani, P., Trotman, J., Sabatelli, L., Waltl, E., Winderlich, M., Sporchia, A., Kurukulasuriya, N., Cordoba, R., Hess, G. & Salles, G., Sept 2023, In: ANNALS OF HEMATOLOGY . 102, 9, p. 2643-2644 2 p.
Research output: Contribution to journal › Correction › peer-review

2 Citations (Web of Science)

Cite this

Nowakowski, G. S., Yoon, D. H., Mondello, P., Joffe, E., Peters, A., Fleury, I., Greil, R., Ku, M., Marks, R., Kim, K., Zinzani, P. L., Trotman, J., Sabatelli, L., Waltl, E. E., Winderlich, M., Sporchia, A., Kurukulasuriya, N. C., Cordoba, R., Hess, G., & Salles, G. (2023). RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. ANNALS OF HEMATOLOGY , 102(7), 1773-1787. https://doi.org/10.1007/s00277-023-05196-4

Nowakowski, Grzegorz S ; Yoon, Dok Hyun ; Mondello, Patrizia et al. / RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. In: ANNALS OF HEMATOLOGY 2023 ; Vol. 102, No. 7. pp. 1773-1787.

@article{91cc275c8ba24cb4a71289f650ec350e,

title = "RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.",

keywords = "RESPONSE CRITERIA, SINGLE-ARM, PHASE-II, MULTICENTER, RITUXIMAB, OUTCOMES",

author = "Nowakowski, {Grzegorz S} and Yoon, {Dok Hyun} and Patrizia Mondello and Erel Joffe and Anthea Peters and Isabelle Fleury and Richard Greil and Matthew Ku and Reinhard Marks and Kibum Kim and Zinzani, {Pier Luigi} and Judith Trotman and Lorenzo Sabatelli and Waltl, {Eva E} and Mark Winderlich and Andrea Sporchia and Kurukulasuriya, {Nuwan C} and Raul Cordoba and Georg Hess and Gilles Salles",

note = "Greil: Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT",

year = "2023",

doi = "10.1007/s00277-023-05196-4",

language = "English",

volume = "102",

pages = "1773--1787",

journal = "ANNALS OF HEMATOLOGY ",

issn = "0939-5555",

number = "7",

}

Nowakowski, GS, Yoon, DH, Mondello, P, Joffe, E, Peters, A, Fleury, I, Greil, R, Ku, M, Marks, R, Kim, K, Zinzani, PL, Trotman, J, Sabatelli, L, Waltl, EE, Winderlich, M, Sporchia, A, Kurukulasuriya, NC, Cordoba, R, Hess, G & Salles, G 2023, 'RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.', ANNALS OF HEMATOLOGY , vol. 102, no. 7, pp. 1773-1787. https://doi.org/10.1007/s00277-023-05196-4

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. / Nowakowski, Grzegorz S; Yoon, Dok Hyun; Mondello, Patrizia et al.
In: ANNALS OF HEMATOLOGY , Vol. 102, No. 7, 2023, p. 1773-1787.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.

AU - Nowakowski, Grzegorz S

AU - Yoon, Dok Hyun

AU - Mondello, Patrizia

AU - Joffe, Erel

AU - Peters, Anthea

AU - Fleury, Isabelle

AU - Greil, Richard

AU - Ku, Matthew

AU - Marks, Reinhard

AU - Kim, Kibum

AU - Zinzani, Pier Luigi

AU - Trotman, Judith

AU - Sabatelli, Lorenzo

AU - Waltl, Eva E

AU - Winderlich, Mark

AU - Sporchia, Andrea

AU - Kurukulasuriya, Nuwan C

AU - Cordoba, Raul

AU - Hess, Georg

AU - Salles, Gilles

N1 - Greil: Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT

PY - 2023

Y1 - 2023

KW - RESPONSE CRITERIA

KW - SINGLE-ARM

KW - PHASE-II

KW - MULTICENTER

KW - RITUXIMAB

KW - OUTCOMES

U2 - 10.1007/s00277-023-05196-4

DO - 10.1007/s00277-023-05196-4

M3 - Original Article

C2 - 37171597

SN - 0939-5555

VL - 102

SP - 1773

EP - 1787

JO - ANNALS OF HEMATOLOGY

JF - ANNALS OF HEMATOLOGY

IS - 7

ER -

Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I et al. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. ANNALS OF HEMATOLOGY . 2023;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.

Keywords

Access to Document

Research output

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma

Cite this